Journal ArticleOPEN ACCESS

Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine

Clinical and Vaccine Immunology (2012) 19(10) 1697-1699
DOI: 10.1128/CVI.00381-12
47Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Vitetta, E. S., Smallshaw, J. E., & Schindler, J. (2012). Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine. Clinical and Vaccine Immunology, 19(10), 1697–1699. https://doi.org/10.1128/CVI.00381-12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free